FDA’s New Opioid Safety Measures Call for Prescriber Education Programs

The FDA this week announced a new “risk evaluation and mitigation strategy” for extended-release and long-acting opioids, targeting safety measures at more than 20 companies that manufacture the drugs.

Advertisement

Drug manufacturers will be required to offer opioid education programs to prescribers and create FDA-approved patient education materials that address the safe use of the drugs.

The first continuing education activities under the REMS will be offered to prescribers by March 1, 2013, according to an agency release.

Related Articles on Pain Management:

Pain Management Physician to Join Neuroscience Clinic
Pain and Spine Specialists of Maryland Launches New Clinic
Purdue Pharma Plans Pediatric OxyContin Trial

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.